Oral Anticoagulation Should Be the Default Strategy After LAAC

Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of patients with any cardiovascular disease to include devices, drugs, and digital health care products listed below:

• Consultant Fee/Honoraria/Speaker's Bureau (Personal) - Abbott Vascular; Boston Scientific Corporation; Medtronic; W.L. Gore & Associates; Baylis Medical; Acutus; BioSense Webster; Shockwave
• Equity/Stock(s)/Options (Personal) - Indian Wells; Intershunt